Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO) (PRECESTO)

• ClinicalTrials.gov Identifier: NCT06091826
• Recruitment Status: Completed
• First Posted: October 19, 2023
• Last Update Posted: October 19, 2023
• Sponsor: NFL Biosciences SAS
• Information provided by (Responsible Party): Yves Donazzolo, NFL Biosciences SAS

Tracking Information

• First Submitted Date: February 21, 2023
• First Posted Date: October 19, 2023
• Last Update Posted Date: October 19, 2023
• Actual Study Start Date: February 21, 2023
• Actual Primary Completion Date: September 15, 2023 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: October 18, 2023)

Change of smoking satisfaction [ Time Frame: at Day 4 ]

Success in achieving a 1 point reduction in the mCEQ "Smoking Satisfaction" subscale

• Original Primary Outcome Measures: Same as current
• Change History: No Changes Posted

Current Secondary Outcome Measures (submitted: October 18, 2023)

• Change of smoking satisfaction [ Time Frame: at Day 7, at Day 14, at Day 21 and at Day 28 ]
  Success in achieving a 1 point reduction in mCEQ "Smoking Satisfaction" subscale
• Change in psychological reward, aversion, enjoyment of respiratory tract sensation and craving [ Time Frame: at Day 4, at Day 7, at Day 14, at Day 21 and at Day 28 ]
  Success in achieving a 1 point reduction in mCEQ "Psychological Reward"; "Aversion"; "Enjoyment of Respiratory Tract Sensations"; and "Craving Reduction" subcales
• "Have you found your urges to smoke stronger or weaker than usual in the last 24 hours?" [ Time Frame: at Day 4, at Day 7, at Day 14, at Day 21 and at Day 28 ]
  With response options of "much stronger," "slightly stronger," "same as before," "slightly weaker," and "much weaker"
• "Have you found cigarettes more or less enjoyable than usual in the last 24 hours?" [ Time Frame: at Day 4, at Day 7, at Day 14, at Day 21 and at Day 28 ]
  With response options of "much more enjoyable," "slightly more enjoyable," "same as before," "slightly less enjoyable," and "much less enjoyable"
• Preference question : "Is there one of the two administrations that made you want to quit smoking or reduce your cigarette consumption more than the other?" [ Time Frame: at EOS visit ]
  With response options of administration 1, administration 2, I dont know, imponderable factors (for example covid, death of a relative, job loss, etc.) do not allow me to answer

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO)
• Official Title: Phase II Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO Trial)

Brief Summary

PRECESTO is a randomized, double-blind, cross-over trial on 34 smokers who do not want to stop smoking and get high satisfaction from smoking.

The primary objective is to assess efficacy of NFL-101 in reducing the positive reinforcing properties of cigarettes compared to placebo measured by the modified Cigarette Evaluation Questionnaire (mCEQ) "Smoking Satisfaction" (items 1, 2, and 12) subscale.

Detailed Description

PRECESTO is a monocentric, placebo-controlled, randomized and double-blind Phase 2a exploratory study, with a crossover covering two periods of 28 days each, including 34 smokers who do not want to quit and have high smoking satisfaction. Each participant is his or her own control and receives, on a random and alternating basis, either NFL-101 or the placebo at the start of each of the two periods. At the end of the study, all the participants received one dose of NFL-101 and one dose of the placebo. For each participant, the order in which NFL-101 and the placebo are administered is kept secret. For each period, the participants receive the treatments on day 1 (D1) then answer, with complete independence, the modified Cigarette Evaluation Questionnaire (mCEQ) on days 4 (D4), 7 (D7), 14 (D14), 21 (D21) and 28 (D28).

The objective is to assess the safety and efficacy of NFL-101 as a pretreatment for smoking cessation, NFL-101 beeing administered a few days or weeks before a quit attempt while smokers are asked to smoke ad libitum (meaning to continue either to try to smoke the same amount or to smoke freely). It is indeed recognized that reducing satisfaction from smoking before a quit attempt begins to undermine the learned association between smoking and reward and thus promotes the success of these attempts.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment

Condition

• Smoking Cessation
• Nicotine Dependence

Intervention

• Drug: NFL-101
  Subcutaneous injections
  Other Name: Tobacco leaf extract
• Drug: Placebo
  Subcutaneous injections
  Other Name: Water for injection

Study Arms

• Experimental: NFL-101
  100 μg per subcutaneous injection (in each arm), two injections at day 1
  Intervention: Drug: NFL-101
• Placebo Comparator: Placebo
  Water for Injection (WFI), two injections at day 1
  Intervention: Drug: Placebo

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: October 18, 2023): 34
• Original Actual Enrollment: Same as current
• Actual Study Completion Date: September 30, 2023
• Actual Primary Completion Date: September 15, 2023 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Equipped with a web connection via a computer or tablet;
• Subject currently smoking at least 10 cigarettes per day;
• Exhaled CO ≥ 9 ppm;
• Subject with a mCEQ Satisfaction subscale score ≥ 4
• Subject not wanting to stop smoking (MTSS score ≤ 2)
• Subject not under tobacco cessation therapy since at least 30 days;
• Considered as healthy for the study after a comprehensive clinical assessment (detailed medical history and complete physical examination);
• For women of childbearing potential: commitment to consistently and correctly use of a highly effective contraceptive measure: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner or sexual abstinence for the duration of the trial;
• Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months);
• Negative pregnancy test at screening visit;
• Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests). Individual values out of the normal range can be accepted if judged clinically non relevant by the investigator;
• Negative prick test at screening visit for the whole study product (extract of Tobacco leaf and NaCL), and positive for histamine;
• Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research;
• Subject having signed the informed consent agreement.

Exclusion Criteria:

• Pregnancy and breastfeeding;
• Concomitant participation to another clinical trial;
• Concomitant active infectious diseases;
• Suicidal or depressive state
• Positive results of screening for drugs of abuse
• History or presence of drug or alcohol abuse (alcohol consumption > 40 grams / day);
• Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study (for subjects in France only);
• Subject who, in the judgment of the investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 70 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: France

Administrative Information

• NCT Number: NCT06091826
• Other Study ID Numbers: v1.2
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Yves Donazzolo, NFL Biosciences SAS
• Original Responsible Party: Same as current
• Current Study Sponsor: NFL Biosciences SAS
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Yves Donazzolo, MD; Eurofins Optimed

• PRS Account: NFL Biosciences SAS
• Verification Date: October 2023